First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study

被引：0

作者：

Andreis, D.

Scandurra, G.

Santini, D.

Gucciardino, C.

La Verde, N. M.

Girelli, S.

Alabiso, I.

Saetta, A.

Atzori, F.

Collova, E.

Ferzi, A.

Gori, S.

Lipari, H.

Saggia, C.

Marcon, I.

Generali, D. G.

机构：

[1] AO Ist Ospitalieri Cremona, UO Multidisciplinare Patol Mammaria, Cremona, Italy

[2] Day Hop, Humanitas Ctr Catanese Oncol, Catania, Italy

[3] Univ Campus Biomed Roma, Dipartimento Med Oncol, Rome, Italy

[4] AO Fatebenefratelli & Oftalm, UO Oncol Med, Milan, Italy

[5] Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy

[6] Fdn Ist San Raffaele D Giglio di Cefalu, UO Oncol, Cefalu, Italy

[7] AOU Cagliari, Struttura Complessa Oncol Med, Cagliari, Italy

[8] Osped Civile Legnano, Legnano, Italy

[9] AO Perugia, Oncol Med, Perugia, Italy

[10] Cannizzaro Hosp, Div Med Oncol, Catania, Italy

[11] AOU Osped Maggiore della Carita, SCDU Oncol, Novara, Italy

[12] AO Osped Circolo, UO Oncol, Varese, Italy

[13] Fdn Macchi, Varese, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.e11502

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e11502

引用

页数：1

共 50 条

[31] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC). [J].

Masuda, N. ;

Aogi, K. ;

Ohno, S. ;

Iwata, H. ;

Kashiwaba, M. ;

Fujiwara, Y. ;

Ito, Y. ;

Ueno, T. ;

Saijo, N. ;

Takashima, S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[32] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J].

J. Salvador ;

L. Manso ;

J. de la Haba ;

A. Jaen ;

E. Ciruelos ;

M. C. de Villena ;

M. Gil ;

A. Murias ;

A. Galan ;

C. Jara ;

J. Bayo ;

J. M. Baena ;

J. Casal ;

J. R. Mel ;

I. Blancas ;

P. Sanchez Rvira .

Clinical and Translational Oncology, 2015, 17 :160-166

[33] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer [J].

Salvador, J. ;

Manso, L. ;

de la Haba, J. ;

Jaen, A. ;

Ciruelos, E. ;

de Villena, M. C. ;

Gil, M. ;

Murias, A. ;

Galan, A. ;

Jara, C. ;

Bayo, J. ;

Baena, J. M. ;

Casal, J. ;

Mel, J. R. ;

Blancas, I. ;

Sanchez Rvira, P. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02) :160-166

[34] First-Line Bevacizumab (Bev) Combined With Paclitaxel (pac) In Older Patients (pts) Treated for HER2-Negative Metastatic Breast Cancer (mBC) in a Routine Oncology Practice Study [J].

Foerster, F. ;

Aktas, B. ;

Geberth, M. ;

Tschechne, B. ;

Schneeweiss, A. ;

Salat, C. ;

Tesch, H. ;

Welslau, M. ;

Schmidt, M. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S351-S352

[35] Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data [J].

Inbar, M. ;

Lang, I. ;

Kahan, Z. ;

Greil, R. ;

Beslija, S. ;

Stemmer, S. M. ;

Kaufman, B. ;

Zvirbule, Z. ;

Steger, G. G. ;

Zielinski, C. C. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S346-S346

[36] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France [J].

Petitjean, Audrey ;

Smith-Palmer, Jayne ;

Valentine, William ;

Tehard, Bertrand ;

Roze, Stephane .

BMC CANCER, 2019, 19 (1)

[37] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France [J].

Audrey Petitjean ;

Jayne Smith-Palmer ;

William Valentine ;

Bertrand Tehard ;

Stephané Roze .

BMC Cancer, 19

[38] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer [J].

Miano, S. T. ;

Rossi, G. ;

Marsili, S. ;

Petrioli, R. ;

Pascucci, A. ;

Francini, G. .

ANNALS OF ONCOLOGY, 2015, 26 :22-23

[39] New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting [J].

Cannita, Katia ;

Paradisi, Stefania ;

Cocciolone, Valentina ;

Bafile, Alberto ;

Rinaldi, Lucia ;

Irelli, Azzurra ;

Baldi, Paola Lanfiuti ;

Zugaro, Luigi ;

Manetta, Rosa ;

Alesse, Edoardo ;

Ricevuto, Enrico ;

Ficorella, Corrado .

CANCER MEDICINE, 2016, 5 (09) :2232-2239

[40] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial. [J].

Beslija, S. ;

Brodowicz, T. ;

Greil, R. ;

Inbar, M. J. ;

Kahan, Z. ;

Kaufman, B. ;

Lang, I. ;

Steger, G. G. ;

Stemmer, S. M. ;

Zielinski, C. ;

Zvirbule, Z. .

CANCER RESEARCH, 2011, 71

← 1 2 3 4 5 →